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Abstract
Background: The ALG2-interacting protein X (ALIX)/AIP1 is an adaptor protein with multiple
functions in intracellular protein trafficking that plays a central role in the biogenesis of enveloped
viruses. The ubiquitin E3-ligase POSH (plenty of SH3) augments HIV-1 egress by facilitating the
transport of Gag to the cell membrane. Recently, it was reported, that POSH interacts with ALIX
and thereby enhances ALIX mediated phenotypes in Drosophila.
Results: In this study we identified ALIX as a POSH ubiquitination substrate in human cells: POSH
induces the ubiquitination of ALIX that is modified on several lysine residues in vivo and in vitro. This
ubiquitination does not destabilize ALIX, suggesting a regulatory function. As it is well established
that ALIX rescues virus release of L-domain mutant HIV-1, HIV-1ΔPTAP, we demonstrated that wild
type POSH, but not an ubiquitination inactive RING finger mutant (POSHV14A), substantially
enhances ALIX-mediated release of infectious virions derived from HIV-1ΔPTAP L-domain mutant
(YPXnL-dependent HIV-1). In further agreement with the idea of a cooperative function of POSH
and ALIX, mutating the YPXnL-ALIX binding site in Gag completely abrogated augmentation of
virus release by overexpression of POSH. However, the effect of the POSH-mediated
ubiquitination appears to be auxiliary, but not necessary, as silencing of POSH by RNAi does not
disturb ALIX-augmentation of virus release.
Conclusion: Thus, the cumulative results identified ALIX as an ubiquitination substrate of POSH
and indicate that POSH and ALIX cooperate to facilitate efficient virus release. However, while
ALIX is obligatory for the release of YPXnL-dependent HIV-1, POSH, albeit rate-limiting, may be
functionally interchangeable.
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Background
The release of nascent retrovirus particles requires the
deployment of the ESCRT (endosomal sorting complex
required for transport) to the site of virus budding at the
cell surface [1-4]. ESCRT consists of four sub-complexes
(ESCRT0-III) that normally reside on the cytoplasmic leaf-
let of the membrane of late endosomes where they func-
tion in tandem to target endocytosed plasma membrane
proteins into mutivesicular bodies (MVBs) en route to lys-
osomes [5-7]. Recruitment of ESCRT to the site of virus
budding is facilitated by interaction of specific ESCRT pro-
teins with short peptide sequences termed late (L-)
domains of retroviruses Gag proteins such as the p6 and
p9 of human immunodeficiency virus (HIV)-1 and
equine infectious anemia virus (EIAV), respectively.
ALIX (ALG2 interacting protein X) is a multifunctional
protein adaptor that plays a central role in the regulation
of intracellular protein trafficking and apoptosis. As an
ESCRT-associated regulator of protein trafficking, ALIX
plays an essential role in retrovirus release, an activity that
is dependent on the interaction between the central V-
domain and the L-domain consensus sequence YPXnL in
Gag [8,9]. The function of ALIX to enhance virus release
requires both the amino proximal Bro-domain that binds
the ESCRT-III component CHMP4B as well as the car-
boxyl terminal proline-rich region (PRR) that interacts
with multiple ALIX effectors including the tumor suscep-
tibility gene (Tsg) 101 [9,10]. Tsg101 is a component of
the ESCRT-I and is essential for the release of retroviruses
like HIV-1 that contain a PTAP L-domain motif [1,11].
Based on the fact that ALIX binds both CHMP and Tsg101
and the redundancy of ESCRT-II for HIV-1 release [12], it
has been proposed that ALIX facilitates virus budding by
recruiting ESCRT-III to ESCRT-I to which the nascent virus
initially binds. In agreement with this hypothesis, overex-
pression of the ALIX V-domain potently inhibits HIV-1
release, a dominant negative function that is reversed by
mutations that abolish ALIX-Gag binding [13]. In con-
trast, preventing ALIX-Gag interaction has only a mild
effect on the release of HIV-1 [14], while the ablation of
Tsg101-Gag interaction blocks virus release almost com-
pletely [4,15-17].
In addition to the binding of HIV-1 p6, ALIX was recently
found to bind to nucleocapsid (NC) via its N-terminal
Bro-domain in an RNA independent manner [18]. This
interaction depends on the zinc finger motif in NC which
mediates packaging of genomic RNA into budding viri-
ons. Intriguingly, zinc finger mutant viruses exhibited a
phenotype similar to PTAP mutants, suggesting a func-
tional link between NC and the L-domain in p6 [18].
The  trans-Golgi network (TGN) RING finger protein
POSH (Plenty of SH3) is a scaffold protein that acts as an
E3 ligase and as an activator of the JNK pathway (Jun N-
terminal kinase), a function that is independent of its
ubiquitination activity. Previously it was demonstrated
that the ubiquitination activity of POSH is required for
the trafficking of HIV-1 Gag from the TGN to the plasma
membrane [19]. Subsequent reports implicated the E3
ligase activity of POSH in the degradation of the early
endosome sorting factor Hrs (hepatocyte growth factor-
regulated tyrosine substrate) [20], in the regulation of the
Drosophila immune response by mediating degradation of
the JNK activator TAK-1 (TGF-beta-activated kinase-1)
[21] and in the regulation of calcium homeostasis
through spatial control of HERP (homocysteine-inducible
endoplasmic reticulum protein) [22].
Recent findings identified ALIX along with ALG-2 as bind-
ing proteins of POSH in Drosophila. Thereby, POSH
enhances ALIX mediated phenotypes in transgenic fruit
flies [23]. Most intriguingly, these findings provided a
clue for a possible molecular mechanism by which POSH
regulates virus release in human cells. In the present study,
we therefore investigated whether POSH cooperates with
ALIX in terms of promoting virus release. We hereby
report that ALIX is a POSH ubiquitination substrate. Fur-
ther, we demonstrate that E3 ligase active POSH substan-
tially enhances ALIX-mediated virus release. However,
down-regulation of POSH fails to block ALIX virus pro-
moting activity, indicating that POSH is not obligatory
but rather an auxiliary co-factor for ALIX to facilitate virus
release.
Results
POSH binds to ALIX in human cells
Previous results demonstrated an interaction between
POSH and ALIX in Drosophila. To confirm this interaction
in human cells, detergent extracts from HeLa cells tran-
siently co-expressing epitope-tagged POSH and ALIX were
subjected to immunoprecipitation of ALIX followed by
Western blot analysis. POSH was efficiently co-precipi-
tated by antibodies against ALIX (Figure 1A). Also the
RING finger mutant POSHV14A, which is inactive as an E3
ligase and was previously shown to function in a domi-
nant-negative manner [19], was efficiently co-immuno-
precipitated using anti-ALIX antibodies (Figure 1A). The
amount of ALIX-bound POSH was directly proportional
to the amount of expressed POSH. Thus, POSHV14A
mutant that expresses at higher levels than wild-type
POSH also shows increased binding to ALIX.
To ascertain that POSH binds directly to ALIX rather than
through the mediation of another cellular factor, bacteri-
ally expressed recombinant POSH and ALIX were incu-
bated in vitro and subsequently immunoprecipitated with
antibodies against FLAG-tagged ALIX followed by Western
blot analysis with POSH specific antibodies. ConsistentBMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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with in vivo data, POSH was efficiently co-precipitated by
antibodies against ALIX, indicating that POSH directly
interacts with ALIX (Figure 1B).
ALIX is a POSH ubiquitination substrate
The finding that ALIX associates with POSH prompted us
to test whether ALIX is a POSH ubiquitination substrate.
To investigate this we employed a HeLa H310A cell line in
which the POSH gene is efficiently silenced due to consti-
tutive expression of a POSH specific shRNA [22]. These
cells were co-transfected with ALIX, HA-tagged ubiquitin
and either RNAi insensitive wt POSH or POSHV14A. Subse-
quent analysis of immunoprecipitated ALIX by Western
blot with anti-HA revealed that POSH, but not POSHV14A,
induced the formation of high molecular weight ALIX-
ubiquitin adducts (Figure 2A). It should be noted that the
exogenous overexpression of POSH never exceeds the
endogenous POSH levels and that of ALIX increases cellu-
lar protein level by approximately 10-fold (as determined
by anti-ALIX, data not shown). Thus it is unlikely that the
ubiquitination of ALIX by POSH is due to either non-
physiological E3 levels or substrate concentration that
could induce otherwise a non-physiological enzyme-sub-
strate interaction.
To discern whether POSH ubiquitinates ALIX directly or
rather, confers regulation of ALIX ubiquitination indi-
rectly, we tested whether ALIX is a POSH ubiquitination
substrate in vitro. To this end, bacterially expressed recom-
binant ALIX and POSH were incubated in the presence of
ubiquitin, an E1 ubiquitin activating enzyme, an E2 con-
jugating enzyme and ATP in an in vitro ubiquitination
reaction followed by Western blot analysis of the reaction
products with anti-ALIX. The incubation of POSH with
ALIX again produced high molecular ALIX species in an
ATP-dependent fashion (Figure 2B). Together, the in vivo
and in vitro ubiquitination results established that ALIX is
indeed a POSH ubiquitination substrate.
The conjugation of multiple ubiquitin moieties to ALIX
together with the fact that this ubiquitination does not
induce ALIX degradation suggests a conjugation of either
non-canonical poly-ubiquitin chains or multiple mono-
ubiquitin molecules. The best characterized non-canoni-
cal protein polyubiquitination is that formed through
ubiquitin moieties linked by isopeptide linkages via lysine
(K) 63 residue of ubiquitin. This type of polyubiquitin
chain formation is strictly dependent on the activity of the
heterodimeric E2 Ubc13/Uev1 [24,25]. To gain insight
into the type of ubiquitination of ALIX induced by POSH
we sought to further characterize the ubiquitination by
employing the in vitro ubiquitination assay. To this end,
bacterially expressed recombinant ALIX and POSH were
incubated in the presence of ubiquitin, an E1 ubiquitin
activating enzyme, two different E2 conjugating enzymes
(UbcH5c and Ubc13/Uev1) and ATP in an in vitro ubiqui-
tination reaction followed by Western blot analysis of the
reaction products with anti-ALIX. The incubation of
POSH and ALIX with UbcH5c produced high molecular
ALIX species in an ATP-dependent fashion (Figure 2B)
while incubation with Ubc13/Uev1 did not although
POSH is active with Ubc13 for ubiquitination of Herp
[22]. As UbcH5c does not support formation of K63-
linked polyubiquitin chains, the production of high
molecular weight ALIX species is indicative of either mul-
tiple monoubiquitin molecules attached to multiple
lysine residues within ALIX, or formation polyubiquitin
chains linked by any other internal lysine of ubiqitin
POSH and ALIX are interacting proteins Figure 1
POSH and ALIX are interacting proteins. A. Interaction in mammalian cells. Flag-tagged ALIX and V5-tagged POSH-were 
co-expressed in 293-HEK cells. ALIX immune complexes were isolated from cell detergent extracts by immunoprecipitation 
with anti-FLAG and analyzed for the presence of POSH by Western blot with anti-V5. B. Direct interaction in vitro. Bacterially-
expressed POSH (50 ng) and ALIX (50 ng) were incubated in binding buffer as described in Materials and Methods and then 
subjected to immonoprecipitation with anti-FLAG. Immune complexes were subsequently analyzed for the presence of POSH 
by Western blot with anti-POSH (PT1).BMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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ALIX is a POSH ubiquitination substrate Figure 2
ALIX is a POSH ubiquitination substrate. A. Overexpression of POSH induces ALIX poly-ubiquitination. Flag-ALIX and 
V5-POSH were expressed in H310 cells together with HA-ubiquitin. ALIX immune complexes were isolated and ALIX-ubiqui-
tination was detected by Western blot with anti-HA. B. POSH ubiquitinates ALIX in vitro. Bacterially expressed ALIX (50 ng) 
and POSH (40 ng) were incubated in an in vitro ubiquitination reaction with the indicated Ubc's (E2's) as described in Materials 
and Methods. ALIX was subsequently isolated by immunoprecipitation with anti-FLAG and analyzed by Western blot with anti-
FLAG. C. ALIX-linked ubiquitination is independent of K48 residue in ubiquitin. T7-tagged-ALIX was overexpressed in HEK-
293 cells. ALIX immune complexes were subsequently isolated by immunoprecipitation with anti-T7 and incubated in an in vitro 
ubiquitination reaction with POSH and UbcH5c and with either native ubiquitin or UbK48R as described in Materials and 
Methods. Following the ubiquitination reaction, ALIX was isolated by immunoprecipitation with anti-FLAG followed by a strin-
gent wash with buffer containing 0.6% SDS (to disrupt ALIX-POSH interaction and thus ensure detection of ALIX-conjugated 
ubiquitin only).BMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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besides K63. Indeed, when a K48R ubiquitin, (where K48
is replaced by arginine), was employed in the in vitro reac-
tion the polyubiquitinated ALIX species formed by POSH
and UbcH5c were indistinguishable from those formed in
the presence of native ubiquitin (Figure 2C). This result in
conjunction with the inactivity of Ubc13/Uev1a indicates
that POSH induces either poly-ubiquitin chains linked via
any other lysine besides K48 and K63 in ubiquitin, or
poly-mono-ubiquitination where single ubiquitin mole-
cules are conjugated to multiple lysine residues of ALIX.
Multiple ubiquitination sites are targeted by POSH
We next set out to investigate which domain of ALIX is
ubiquitinated by POSH. For that reason, truncation
mutants of ALIX were co-expressed with POSH and HA-
tagged ubiquitin in H310A cells and ALIX-ubiquitin
adducts were determined by Western blot with anti-HA.
The C-terminal PRR of ALIX was the most promising can-
didate to be targeted by POSH as it was shown to interact
with SH3-domains [26]. However, deletion mutants of
the last amino acids still were ubiquitinated by POSH
(Figure 3). Even when the entire PRR was deleted, POSH
still induced the formation of high molecular weight
ALIX-ubiquitin adducts (Figure 3), indicating that POSH
also binds and ubiquitinates regions outside the PRR.
Also a deletion of the N-terminal Bro-domain did not dis-
turb the POSH-ALIX interaction as an N-terminal trunca-
tion mutant of ALIX is still ubiquitinated by POSH (Figure
3). Only the central V-domain was not targeted by POSH,
either for the reason that it does not contain an ubiquiti-
nation site, or that it does not bind to POSH (Figure 3).
POSH enhances ALIX mediated augmentation of virus 
release
Recent studies demonstrated that overexpression of ALIX
can rescue the production of an HIV-1ΔPTAP mutant virus,
that otherwise is severely attenuated due to its L-domain
deficiency [9,14]. We therefore employed a full-length
infectious HIV-1NL4-3 molecular clone, in which the PTAP
motif was replaced by LIRL without affecting the pol ORF
(HIV-1ΔPTAP [27]) to explore the function of ALIX in virus
biogenesis. Consequently, HeLa SS6 cells were co-trans-
fected with HIV-1ΔPTAP together with ALIX and POSH. Gag
processing and release of infectious virions was deter-
mined 24-h post transfection by Western blot and single
round infection of TZM-bl cells. The overexpression of
POSH alone slightly enhanced both the expression of Gag
and the release of virus particles (Figure 4, lane 2), while
overexpression of ALIX dramatically stimulated virus
release by approximately 10-fold (Figure 4, lane 3) as
described previously [9]. However, co-expression of both
exogenous POSH and ALIX further amplified virus pro-
duction up to 25-fold compared to the control (Figure 4,
lane 4), indicating that both POSH and ALIX regulate the
release of L-domain mutant HIV-1 virions in a synergistic
manner.
Measurement of virion associated CA and infectivity as
indication of virus release seems to be over-simplistic in
this case as it is evident that POSH expression also
increased Gag processing (compare intracellular CA in
lanes 1 and 2). Hence it is either that POSH contributed
to virus release by increasing Gag expression (or stability)
POSH targets multiple sites in ALIX Figure 3
POSH targets multiple sites in ALIX. T7-tagged ALIX derivatives were expressed in HEK-293 cells and then subjected to 
immunoprecipitation with anti-T7. Isolated ALIX was subsequently incubated in an in vitro ubiquitination reaction and ALIX-
ubiquitin conjugation was analyzed as described in Material and Methods and in the legend to figure 2.BMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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or that it functioned through a different mechanism. To
discern between these possibilities we quantified the
Western blot presented in figure 4A and subsequently
determined the ratios between intracellular CA and virion
CA and total Gag as measurements of Gag processing and
virus release, respectively (Figure 4B). According to these
measurements, expressed relative to the corresponding
ratio in the control, POSH had a minor effect on Gag
processing, while ALIX stimulated processing by approxi-
mately three-fold (Figure 4B, right panel). POSH in the
presence of ALIX did not further stimulate Gag processing.
Similarly, POSH minimally affected mutant virus release
while ALIX stimulation was over 2.5-fold (Figure 4B, left
panel). Yet, despite having no effect by itself, in the pres-
ence of ALIX, POSH further stimulated virus release up to
4-fold. Thus, these quantifications indicate that the syner-
gistic contribution of POSH is through a mechanism inde-
pendent of the increase of Gag expression.
As we found that POSH ubiquitinates ALIX, we conse-
quently wanted to test whether the enhancing effect of
POSH on virus release is dependent on its ubiquitination
activity. To this end, the enzymatic inactive POSHV14A
mutant was tested for the ability to support virus release.
Overexpression of POSHV14A alone in HeLa SS6 cells did
not influence overall virus production (Figure 4A, lane 5)
but inhibited relative Gag processing and virus release
indicating a dominant negative effect (Figure 4B, lane 5).
In contrast to wt POSH, the POSHV14A mutant did not fur-
ther support ALIX mediated rescue of the HIV-1ΔPTAP.
Moreover, consistent with a dominant negative effect,
overexpression of POSHV14A even slightly suppressed the
stimulating effect of ALIX overexpression on virus produc-
tion (Figure 4A and 4B, lane 6).
Next we measured the requirement for POSH for HIV-
1ΔPTAP release at varying ALIX concentrations. To this end
H310A cells were co-transfected with HIV-1ΔPTAP  and
increasing amounts of ALIX expression plasmids co-
expressed with either empty or POSH expression plasmid.
Subsequent determination of virus release (Figure 5)
showed that under conditions where ALIX was rate limit-
ing, POSH consistently enhanced mutant virus release by
approximately three fold. At higher concentration of
ALIX, the enhancing effect of POSH was diminished, most
likely due to saturation effects.
To further investigate the cooperative function of POSH
and ALIX we tested whether the enhancing effect of POSH
on virus release depends on the interaction between ALIX
and HIV-1 Gag. Previous studies already indicated that
POSH did not directly interact with HIV-1 Gag [19]. Con-
sequently, it can be excluded that the stimulatory effect of
POSH on virus release resulted from a direct interaction of
POSH with Gag. Yet, abrogating the interaction between
ALIX and Gag should provide further indication whether
POSH requires ALIX to stimulate virus production. There-
fore, we investigated the ability of POSH to enhance ALIX-
dependent virus release of HIV-1ΔPTAP ALIX binding site
(YPXnL) mutant, HIV-1ΔPTAP/ΔYP. To this end, POSH was
co-expressed together with HIV-1 p6 ALIX binding site
variants. The results depicted in figure 6 show that in the
presence of the intact ALIX binding site in p6, POSH was
able to enhance HIV-1ΔPTAP release (Figure 6, lanes 1 and
2). Consistent with previous results [9], the secondary
ΔYP mutation further reduced HIV-1 release and infectiv-
ity by an additional 5-fold (Figure 6, lanes 1 and 3) as this
mutation blocks ALIX-Gag interaction and as a result, the
ability of ALIX to stimulate virus release. Overexpression
of POSH had only slight effect on the release and infectiv-
ity of the HIV-1ΔPTAP/ΔYP double mutant virus, indicating
that POSH requires the interaction of ALIX and Gag to
substantially enhance virus production of a HIV-1ΔPTAP
mutant.
ALIX mediated rescue of HIV-1 L-domain mutant occurs 
independently of POSH
Thus far, it could be demonstrated that POSH stimulated
ALIX-mediated YPXnL-dependent virus release and that
this effect is depended on its ubiquitination activity. To
further elucidate the functional relationship between
POSH and ALIX, we investigated the dependence of ALIX-
mediated virus release on the ubiquitination by POSH. To
address this question, endogenous levels of POSH were
knocked down by RNAi in order to determine whether
ALIX could enhance virus release in the absence of POSH.
As shown in figure 7, significant (approximately 70%)
knock down of endogenous levels of POSH by RNAi had
no influence on ALIX-mediated rescue of the HIV-1ΔPTAP
mutant, indicating that ALIX retained its activity even
when endogenous POSH levels were reduced (Figure 7,
compare lanes 1 and 2 to 3 and 4). Similar results were
obtained when the POSH deficient H310A HeLa cell line
was employed [22] and the ability of ALIX to rescue the
release HIV-1 L-domain mutants in these cells was com-
pared to the control cell line H314A (data no shown).
Hence, it appears that the virus release enhancing func-
tion of ALIX can be stimulated by POSH-mediated ubiq-
uitination, while in contrast down-regulation of POSH
does not significantly influence the ALIX activity.
Discussion
ALIX is a proline rich, multifunctional protein that has
been implicated in numerous cellular functions such as
regulation of apoptosis and endocytotic protein traffick-
ing [26,28]. ALIX was shown to associate with the MVB
pathway and thereby being involved in budding of envel-
oped viruses. More recently it was demonstrated that ALIX
as an ESCRT-III associated protein is also involved in the
terminal stages of cytokinesis, where it is recruited to theBMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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Wild type POSH but not the ubiquitination inactive V14A mutant enhances rescue of virus production by ALIX Figure 4
Wild type POSH but not the ubiquitination inactive V14A mutant enhances rescue of virus production by 
ALIX. A: The left panel shows Virus release, Gag processing and POSH and ALIXexpression analyzed by Western blot. The 
right panel shows the amounts of infectious units released from the cells analyzed by β-galactosidase quantification after infec-
tion of TZM-bl cells. Shown are virus infectivities relative to the HIV-1ΔPTAP control ± SD. HIV-1ΔPTAP-mutant was co-trans-
fected with: lane 1, empty pcDNA3.1V5His; lane 2, a V5-POSH expression plasmid; lane 3, a FLAG-ALIX expression plasmid; 
lane 4, vectors expressing FLAG-ALIX and V5-POSH; lane 5, a plasmid encoding POSHV14A; lane 6, vectors encoding FLAG-
ALIX and POSHV14A. RP0: ribosomal P0 antigen. B: Quantification of Western blot data using AIDA Software (Raytest). The 
left panel shows the amount of Gag release determined by the ratio of virus associated Gag/total Gag expressed relative to the 
control set to 1. The right panel shows the processing of Gag in the cell lysates as determined by the ratio of CA/total Gag 
expressed relative to the control set to 1.BMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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midbody through binding to Cep55 (centrosome associ-
ated protein 55) [29,30]. Biogenesis of intra-endosomal
vesicles in MVBs, midbody abscission during cytokinesis
and virus budding are topologically equivalent inasmuch
as the final step, the pinching off the membrane-stalk, is
regulated by the ESCRT.
Due to its multitasking nature, the function of ALIX is
tightly regulated by its interaction partners. As already
demonstrated earlier by others, ALIX is phosphorylated by
the Src thyrosine kinase, which regulates its association
with membranes and cytoskeleton as well as its affinity to
binding partners SETA/CIN85 and Pyk2 that are involved
in receptor downregulation and cell adhesion, respec-
tively [31].
In this study we propose a role for ubiquitination in the
regulation of ALIX function. We found, that the TGN-
associated scaffolding protein POSH, which exhibits E3-
ligase activity mediated by its N-terminal RING-domain,
ubiquitinates ALIX. Intriguingly, this ubiquitination does
not induce proteasomal degradation of ALIX, as there was
no reduction in the level of intracellular ALIX upon POSH
overexpression. Moreover, as it could be excluded that the
ubiquitin chains are linked via K48 of ubiquitin, the non-
canonical ubiquitination apparently has a regulatory
function. While it could be established that POSH targets
multiple lysine residues in ALIX, the detected high molec-
ular ALIX species possibly arise from conjugation of mon-
omeric ubiquitin moieties to several lysine residues. ALIX
contains altogether 65 lysine residues from which 33 were
predicted by computational analysis to be accessible for
ubiquitination (ubiquitin nuggets, http://ubpred.org/).
However, the exact nature of this ubiquitination remains
obscure. Given that ALIX is ubiquitinated in the presence
of UbcH5c but not in the presence of Ubc13/Uev1 it is
likely that POSH either induces multi-ubiquitination on
several lysine residues within ALIX or poly-ubiquitin
chains linked via ubiquitin lysine residues other than K48
and K63 (e. g. K6, K11, K27, K29, and K33) as has been
recently described [32]. The functional significance of
these types of ubiquitinations on target proteins is still
poorly understood.
Besides its numerous functions in regulating cellular path-
ways, ALIX was described as binding partner of HIV-1 p6
and EIAV p9 thereby being involved in budding and
release of these retroviruses [8,9]. Previously it was dem-
onstrated that the ubiquitination activity of POSH is
required for HIV-1 particle production by facilitating Gag
trafficking from the TGN to the cell membrane and thus,
stimulates the release HIV-1 particles [19]. The finding
that there is a functional interaction between POSH and
ALIX prompted us to investigate the importance of this
interaction for virus release. Though the specific regula-
tion conferred on ALIX through POSH-dependent ubiqui-
tination is unclear, the data indicates that both proteins
somehow cooperate to promote virus release: Overexpres-
sion of POSH substantially stimulated the ALIX mediated
rescue of an HIV-1ΔPTAP mutant, the stimulatory effect of
POSH on virus production was blocked by abrogating
Gag-ALIX interaction through introduction of specific
mutations within Gag that prevented ALIX binding and
the enhancing effect of POSH was completely abolished
when its ubiquitination activity was disrupted due to a
RING finger mutation (POSHV14A). However, the minor
residual activity of POSH observed when ALIX-Gag inter-
action was blocked by the ΔYP mutation in the L-domain
containing p6 Gag protein might indicate that POSH also
regulates another factor along the pathway that mediates
virus release. This together with the fact that siRNA-medi-
ated knockdown of POSH fails to block the function of
ALIX raises the question of whether the cooperative func-
tion of POSH and ALIX in terms of promoting virus
release is a result of a direct interaction between both pro-
teins, or a consequence of an independent positive role of
POSH-mediated ubiquitination somewhere else in the
pathway. The observation that POSH, which by itself does
not interact detectably with Gag, ubiquitinates ALIX is
consistent with a model whereby the binding of Gag to
ALIX meditates virus egress while POSH acts as an auxil-
iary factor. Since downregulation of POSH has no detect-
able influence on the function of ALIX, it is either that
POSH is not strictly required or that the POSH function
can be substituted by another E3-ligase. Similar to Tsg101,
which is also substrate for two different E3 ligases, namely
POSH stimulates ALIX mediated virus release Figure 5
POSH stimulates ALIX mediated virus release. 
H310A cells were co-transfected with HIVΔPTAP, increasing 
amount of ALIX plasmids, and either a control DNA (black 
squares) or a POSH expression vector (open circles). The 
amount of infectious units released from the cells was ana-
lyzed by β-galactosidase quantification after infection of 
TZM-bl cells.BMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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POSH mediated enhancement of virus release requires a functional ALIX binding site in Gag Figure 6
POSH mediated enhancement of virus release requires a functional ALIX binding site in Gag. Virus release, Gag 
processing, and exogenous expression of POSH were analyzed by Western blot (upper panel). Amount of infectious units 
released from the cells was analyzed by β-galactosidase quantification after infection of TZM-bl cells (lower panel). Shown are 
infectivities relative to the HIV-1ΔPTAP control ± SD. Lane 1 shows HIV-1ΔPTAP mutant co-transfected with the empty 
pcDNA3.1V5His control vector, lane 2 shows HIV-1ΔPTAP mutant co-transfected with a V5-POSH expression plasmid, lanes 3 
and 4 show the HIV-1ΔPTAP/ΔYP double mutant co-transfected with the empty control plasmid and the vector expressing V5-
POSH, respectively.BMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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Tal (Tsg101 associated ligase) and Mahogunin [33,34],
ALIX may be ubiquitinated by an additional E3 ligase,
when POSH is downregulated.
Until now, the molecular mechanism by which ALIX sup-
ports virus release is unresolved. Apparently, it requires
the interaction of the N-terminal Bro-domain of ALIX
with the ESCRT-III component CHMP4B as mutations in
ALIX that prevent ALIX/ESCRT-III interaction abolish the
ability of ALIX to rescue HIV-1 L-domain mutants [9,10].
In addition, the C-terminal PRR of ALIX was shown to be
essential for virus release [9,10], however, the nature of
this activity is currently unknown. Furthermore, as ALIX
fulfills several distinct cellular functions, it is possible that
ubiquitination by POSH regulates a function that is
redundant for virus release. That the ubiquitination of
ALIX by POSH might not be essential for virus release is
supported by the results that show lack of correlation
between the requirement for ALIX ubiquitination and for
the capacity of ALIX to support virus release. For example,
ALIX truncation mutants that cannot promote virus
release such as the ΔBro and the ΔPRR are similarly ubiq-
uitinated and both ubiquitination patterns are similar to
that of native ALIX.
Previous studies implicated POSH as a regulator of Gag
transport from the TGN to the cell membrane, a function
that precedes ESCRT-mediated virus budding from the
membrane. The function of POSH mediated ubiquitina-
tion of ALIX may accelerate a step of Gag transport prior
to the virus assembly at the cell membrane. As the rate-
limiting step of virus production of HIV-1ΔPTAP mutant vir-
ions is the ESCRT-dependent release of virus particles
from the cell membrane, inhibition of steps earlier in the
pathway would not show a significant phenotype as long
as enough Gag is transported to the cell membrane.
However, besides its role in ESCRT, ALIX was initially
identified as interaction partner of ALG-2, a calcium bind-
ing protein that is necessary for induction of apoptosis
[35,36]. The observation that POSH binds both, ALIX and
ALG-2 in a calcium dependent manner [23] together with
the implicated role of POSH in the induction of apoptosis
and neuronal differentiation [37-39] suggest a functional
role for POSH and ALIX in the regulation of apoptosis and
calcium metabolism. Further evidence for this hypothesis
comes from findings that POSH regulates calcium home-
ostasis through spatial control of HERP [22]. The fact, that
ALIX links ALG-2 and ESCRT pathways [40] might indi-
cate that these pathways are somehow connected and are
utilized by HIV-1.
It has been reported that actin polymerisation is essential
for Gag transport of EIAV to the plasma membrane and
the subsequent disassembly of actin filaments facilitates
virus budding and virion release from the cell membrane
[41]. ALIX, that contains actin and alpha actinin binding
sites, also plays a pivotal role in actin organisation. Pan
and colleagues reported that ALIX expression in a fibrob-
last cell line was required to maintain actin-based struc-
tures such as stress fibers and lamellipodia [42].
We have no evidence for direct interaction between POSH
and actin. Nevertheless, considering the interaction
between POSH and ALIX, the actin interaction properties
of ALIX and the requirement for actin dynamics for virus
production and release, we propose (a model) whereby
both proteins cooperate at the plasma membrane where
ALIX serves a dual function: it bridges between Gag and
actin through respective binding sites while it recruits
ESCRT to initiate virus budding. POSH may regulate dis-
assembly of actin from Gag, possibly through ubiquitina-
tion of ALIX, thereby facilitating detachment of nascent
virus particles from the cell membrane.
The model is consistent with the absolute requirement for
ALIX as it is essential for mutant virus budding. Likewise,
the model is in agreement with overexpression of POSH
enhancing virus release possibly by increasing the rate of
actin disassembly.
Finally, it should to be considered that POSH also inter-
acts with another ESCRT-associated protein as it was
shown to ubiquitinate Hrs, which in contrast to ALIX, is
subsequently targeted for proteasomal degradation. Hrs
interacts with the ESCRT-I components Tsg101 and
HCRP1/Vps37A and C-terminal fragments of Hrs that
interact with Tsg101 interfere with HIV-1 particle produc-
tion [43]. Thus, it has to be considered that overexpres-
sion as well as downregulation of POSH may also regulate
HIV-1 release distant to the hereby described POSH-ALIX
interaction and overlapping effects may account for the
partial nature of the phenotype described.
Conclusion
We have identified ALIX as an ubiquitination substrate of
POSH and indicate that both proteins are involved in the
process of YPXnL-dependent HIV-1 release. However,
while ALIX is obligatory for the release of HIV-1 L-domain
mutant viruses, POSH, albeit rate-limiting, may be func-
tionally interchangeable for the function of ALIX.
Methods
Plasmids and siRNA
The HIV-1ΔPTAP mutant is based on the HIV-1 molecular
clone NL4-3 [44] in which the 7PTAP10 L-domain motif
was replaced by 7LIRL10 without affecting the overlapping
pol-reading frame [27]. In the HIV-1ΔPTAP/ΔYP, in addition
to the PTAP domain, the 36YP37 of the 36YPXn = 3L41 ALIX
binding motif in p6 was mutated to 36SR37 by site directed
mutagenesis, without affecting the overlapping pol-read-
ing frame. Plasmids pcDNA3.1-POSH-V5-His andBMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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ALIX mediated rescue of HIV-1 L-domain mutant occurs independently of POSH Figure 7
ALIX mediated rescue of HIV-1 L-domain mutant occurs independently of POSH. Endogenous levels of POSH 
were knocked down by RNAi in order to determine, whether ALIX can enhance virus release in the absence of POSH. HIV-
1ΔPTAP was co-transfected with a control siRNA together with either an empty plasmid or an ALIX expression plasmid (lanes 1 
and 2 respectively). HIV-1ΔPTAP was co-transfected with a POSH specific siRNA and either an empty plasmid or an ALIX 
expression plasmid (lanes 3 and 4 respectively). RP0: ribosomal P0 antigen.BMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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pcDNA3.1-POSH-V14A-V5-His were described previously
[19]. Plasmids containing ALIX cDNA were derived from
IMAGE clone IMAGE: 4340998. For expression in mam-
malian cells, the 5' region of the cDNA was PCR amplified
in frame with either T7 tag or a FLAG tag peptide
sequence, and ligated back into the same plasmid to cre-
ate pCMV-T7-ALIX and pCMV-FLAG-ALIX. For bacterial
expression FLAG-ALIX or a region containing residues
200–320 were cloned into pGEX-6P (GE Healthcare). To
the full-length ALIX an N-terminal six histidine tag was
also added. The short interfering RNA (siRNA) against
POSH was described in [19]. The H310A cell line that sta-
bly express POSH-specific short hairpin (sh)RNA was pre-
viously described [22].
Production of recombinant ALIX
For expression of recombinant full-length ALIX, GST-
FLAG-ALIX-6xHIS was induced with IPTG at 22°C for 3 h.
Protein was purified by glutathione chromatography dia-
lyzed into 20 mM Tris-HCl pH 7.6, 100 mM NaCl, 20 mM
Imidazole, 10 mM β-mercaptoethanol and further puri-
fied by Ni-NTA (Qiagen) chromatography and further
dialyzed into 20 mM Tris pH 7.6, 1 mM DTT, 0.5 mg/ml
ovalbumin.
Antibodies
Antibodies against FLAG and V5 were obtained from
Sigma and Invitrogen, respectively. Ubiquitin mono-
clonal antibody FK2 was from mouse anti-POSH mono-
clonal antibody was previously described [22]. The
human anti-HIV-1 Gag antiserum was provided by the
AIDS Research and Reference Reagent Program. For anti-
ALIX sera preparation GST-ALIX (200–320) was expressed
in E. coli BL21 by IPTG induction. Protein was purified
from cell lysate by glutathione chromatography and the
GST moiety removed by digestion with PreScission pro-
tease (GE Healthcare). The isolated polypeptide was used
to raise antibodies in rabbits (Sigma-Aldrich, Israel).
Cell culture
HEK-293T, HeLa SS6, H310A, H314A [22], and TZM-bl
cells were cultured in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% inactivated
fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml pen-
icillin and 100 μg/ml streptomycin. H314A and H310A
cells were cultured in the same medium but additionally
supplemented with 0.5 mg/ml hygromycin Jurkat T-cells
were maintained in RPMI 1640 supplemented with 10%
inactivated FCS, 2 mM L-glutamine, and 100 U/ml peni-
cillin and 100 μg/ml streptomycin.
In vitro ALIX ubiquitin conjugation assays
Recombinant ALIX: Purified recombinant ALIX (50 ng)
was incubated with 50 nM of recombinant E1, 0.3 μM of
UbcH5c or Ubc13/Uev1a (where indicated), 13 nM of
bacterially expressed maltose-binding protein (MBP)-
POSH [19] in a final volume of 25 μl containing 40 mM
Tris-HCl pH 7.5, 1 mM DTT, 2 mM ATP, 5 mM MgCl2, 5
× 10-3 (vol/vol) Tween 20 and 2 μg ubiquitin. After incu-
bation for 45 min at 30°C, ALIX was isolated via immu-
noprecipitation. The ALIX immune complexes were
washed in a buffer containing 0.6% SDS (to dissociate
POSH) and ubiquitin conjugation was subsequently
detected by Western blot with anti-ubiquitin (FK2).
Cell-expressed ALIX: 3 μg of T7-tagged ALIX or ALIX trun-
cation mutants expressing plasmids (as indicated in the
figure legends) were transfected each into HEK-293 cells
(5.4 × 106 cells per 10 cm dish). One day after the trans-
fection, ALIX was immunoprecipitated with anti-T7 and
protein G beads. One third of the ALIX beads packed vol-
ume was transferred into a fresh tube and subsequently
incubated in an in vitro ubiquitination reaction as
described above. ALIX ubiquitination was detected by
western blot analysis with anti-ubiquitin as described
above.
In vivo ALIX ubiquitination
HeLa SS6 cells or H310 cells (9 × 105 cells in a 6-well
plate) were transfected with T7-ALIX plasmid (0.5 μg) and
V5-POSH (1 μg) or V5-POSH V14A (0.2 μg) and HA-
tagged ubiquitin (1 μg). The day after the transfection
ALIX was isolated by immunoprecipitation with anti-T7.
Ubiquitination of ALIX was detected by Western blot
analysis of the ALIX immune complexes with anti-HA.
ALIX-POSH binding assays
Interaction in cells: FLAG-tagged ALIX (3 μg) and V5-
POSH (6 μg) or V5-POSH V14A (1.2 μg) were co-
expressed in HEK 293 cells. One day after the transfection
cells were extracted in lysis buffer containing 10 mM Tris
HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2 and 1% Octyl β-
D-glucopyranoside (Ultrol grade, Calbiochem). ALIX was
isolated by immunoprecipitation with anti-FLAG beads.
The beads were washed three times with lysis buffer and
subsequently resolved in a 7.5% SDS gel. ALIX-bound
POSH was detected by Western blot analysis with anti-V5.
Interaction between bacterially-expressed ALIX and
POSH: Bacterially expressed GST-Flag-ALIX and POSH
(50 ng each) were incubated in lysis buffer as described
above. After incubation for at 30°C for 45 min. ALIX was
isolated by immunoprecipitation as described above. The
ALIX beads were washed three times with lysis buffer and
then subjected to Western blot analysis with anti-POSH
(PT1).
Virus release and infectivity assays
HeLa SS6, H310A and H314A cells (9 × 105 cells/well in
6-well plates) were transfected with 1 μg of HIV-1ΔPTAPBMC Biochemistry 2009, 10:12 http://www.biomedcentral.com/1471-2091/10/12
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plasmid together with 0.2 μg of ALIX expression vector, 1
μg POSH expression vector and 0.2 μg POSHV14A expres-
sion vector per well. DNA content was adjusted to 4 μg
total DNA by addition of empty pcDNA3.1V5His and
transfection was carried out with 10 μl Lipofectamine™
2000 (Invitrogen) per well according to manufacturer's
instructions. For RNAi HeLa SS6 (2 × 105 cells/well) cells
were initially transfected with siRNA using Lipo-
fectamine™ 2000 according to manufacturer instructions
and split the next day. 48 h after the initial transfection,
cells were co-transfected with another portion (one fourth
of first transfection) of siRNA together with plasmids
encoding ALIX (0.1 μg), POSH (1 μg), V14A (0.2 μg) and
HIV-1ΔPTAP (1 μg). Cells and virions were harvested 24 h
post transfection. Proteins were extracted by RIPA (1%
NP-40, 0.5% Na-DOC, 0.1% SDS, 0.15 M NaCl; 50 mM
Tris-HCl pH 7.4; 5 mM EDTA) lysis and analyzed by West-
ern blotting. Cell debris from virus containing superna-
tant was removed by centrifuging at 1000 × g for 5 min
and 8000 × g for 10 min. Virions were subsequently pel-
leted over 20% sucrose at 20000 × g for 90 min, re-sus-
pended in 1 ml of PBS, pelleted again for 20000 × g for 90
min to remove serum albumins and finally analyzed by
Western blotting. HIV-1-infectious titers were assayed by
single round infection of Hela TZM-bl cells. 4000 cells per
well in 96 well plate were infected by overnight incuba-
tion with prepared virus supernatants in a total volume of
100 μl in the presence of 10 μg/ml polybrene. To avoid
spread of infection, cells were washed and dextran-sulfate
(100 μg/ml) was added 16 h post infection. Three days
post infection, cells were lysed in 40 μl CAT lysis buffer
(Roche) and β-galactosidase activity was determined.
Therefore, cell 35 μl of the cell lysate were added to 215 μl
Z buffer pH 7.0 (60 mM Na2HPO4; 40 mM NaH2PO4; 10
mM KCl; 10 mM MgSO4; 0.05 mM β-mercaptoethanol;
0,08% SDS) containing 0.375 mg chlorophenolred β-D-
galactopyranoside (Roche), incubated at room tempera-
ture 1–8 h and read at 574 nm.
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